Company intelligence / Profile preview
STENOCARE
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
Overview
Stenocare has received regulatory approvals for its prescription-based medical cannabis oil products in Denmark and several other European and international markets. The company offers a portfolio of at least thirteen approved products across six countries. Its "premium" product line uses targeted lymphatic absorption technology to enhance uptake regardless of food intake. Clinical results are not detailed publicly but the company’s commercial presence indicates successful regulatory review for safety and efficacy as required by local authorities.
- Therapeutic areas
- NeurologyOther
- Modalities
- Small molecule (cannabinoids)Oil-based drug formulation
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on STENOCARE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STENOCARE.